Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia

The University of Texas Health Science Center at San Antonio105 enrolled

Overview

This study will compare the effectiveness of three treatments in improving medication adherence, symptoms, and function in people with schizophrenia.

Schizophrenia is a chronic and severely disabling mental disorder. People with schizophrenia may experience hallucinations, delusions, disordered thinking, movement disorders, social withdrawal, and cognitive deficits. Antipsychotic medications have been effective in alleviating many of the symptoms of schizophrenia and improving the lives of people with the disease. It is well established, however, that poor adherence to antipsychotic medications can lead to relapse and rehospitalization. Cognitive deficits often contribute to treatment nonadherence by compromising patients' capacity to establish routines for taking medication. Cognitive adaptation training (CAT) is a treatment approach designed to alter the physical environment of individuals with schizophrenia to compensate for cognitive deficits and improve adaptive function. For example, various environmental supports, such as signs, checklists, and electronic devices, are used to remind patients to take their medication. Studies have shown that CAT's support system led to better treatment outcomes than those produced by standard care in people with schizophrenia. This study will compare the effectiveness of two CAT treatments versus standard treatment in improving medication adherence, symptoms, and function in people with schizophrenia. After providing a blood sample, participants in this single-blind study will be randomly assigned to Full-CAT, Pharm-CAT, or treatment as usual for 9 months. Participants receiving treatment as usual will not receive CAT support. Full-CAT will entail a comprehensive use of environmental supports to improve multiple areas of adaptive functioning. Pharm-CAT will provide support for medication adherence only. Participants assigned to one of the two CAT groups will receive weekly treatments in their homes. All participants will report to the study site once every 3 months to assess medication adherence, symptomatology, and adaptive functioning. Participants will be interviewed by the study physician for 2 to 3 hours at each visit. A member of the study staff will also visit each participant's home at a random, unannounced time once every 3 months to obtain a blood sample. Follow-up visits will occur 3 and 6 months following the end of treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

105

Conditions

Schizophrenia

Interventions

Cognitive Adaptation TrainingBEHAVIORAL

Environmental supports for all independent living skills

Pharm-Cognitive Adaptation TrainingBEHAVIORAL

Environmental supports for medication and appointment adherence

Treatment as usualOTHER

Medication follow-up and limited case management provided by local community mental health authority

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of schizophrenia or schizoaffective disorder * If entering the study as an inpatient, hospitalization was recent * Currently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended * Assumes primary responsibility for taking medication * Currently living in a stable environment Exclusion Criteria: * History of significant head trauma, seizure disorder, or mental retardation * History of alcohol or drug abuse or dependence within 1 month prior to study entry * History of violence within 6 months prior to study entry

Locations (1)

University of Texas Health Science Center

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Medication Adherence-pill Count

% medication taken as determined by unannounced pill counts conducted in the home on 2 occasions in each 3 month period. 1 Final score for endpoint created by averaging scores for 9 months of treatment and 6 months of follow up.

Time frame: 1 final score combined for endpoint for 9 months of treatment and 6 months follow up

Positive Symptoms

Positive symptoms subscale of the Brief Psychiatric Rating Scale includes delusions, hallucinations, conceptual disorganization and suspiciousness-Mean score averaging these items, variability 1-7. Higher scores reflect higher level of symptoms. 1 Final score for endpoint created by averaging scores for 9 months of treatment and 6 months of follow up.

Time frame: 1 final endpoint least sq mean combining 9 months of treatment 6 months of follow up

Social and Occupational Functioning Scale Score

Scores range from 0 to 100 with higher scores reflecting better functioning. 1 Final score for endpoint created by averaging scores for 9 months of treatment and 6 months of follow up.

Time frame: 1 endpoint ls means combining 9 months of treatment and 6 months follow up

Number of Patients Surviving Without Relapse/Exacerbation

A relapse was scored (only for patients meeting criteria for remission) if scores on any of the 4 items assessing positive symptoms on the Brief Psychiatric Rating Scale increased a minimum of 2 points to a score of 5 or higher, if the patient was suicidal, if the patient was hospitalized, or if the patient was unable to care for themselves without continual supervision

Time frame: 9 months of treatment 6 months follow up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.